Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Clin Pharmacol. 2009 Mar;65(3):309-14. doi: 10.1007/s00228-008-0600-9. Epub 2008 Dec 24.

Persistence of antimuscarinic drug use.

Author information

1
Department of Obstetrics and Gynecology, Glostrup Hospital, DK-2600, Glostrup, Denmark. soren@brostrom.dk.

Abstract

PURPOSE:

Evidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies.

METHODS:

All prescriptions for drugs in ATC category G04BD were retrieved for the period 1999-2006 from a regional database with complete capture of all reimbursed prescriptions. Kaplan-Meyer curves were generated for duration of treatment for each substance and analyzed for determinants of termination.

RESULTS:

With the exception of trospium chloride, all drugs had continuation rates of less than 50% at 6 months, less than 25% at 1 year, and less than 10% at 2 years and longer. Trospium chloride, however, exhibited continuation rates of 46% at 6 months, 36% at 1 year, 22% at 2 years, and 16% at 3 years.

CONCLUSIONS:

In a setting of socialized medicine, we found higher continuation rates than previously published. Interestingly, we found that one of the older drugs on the market, trospium chloride, had a strikingly longer retention rate than other drugs.

Comment in

PMID:
19107469
DOI:
10.1007/s00228-008-0600-9
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center